We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

77 hedge funds and large institutions have $43.2M invested in Oramed Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more capital invested

Capital invested by funds: $25.5M → $43.2M (+$17.7M)

67% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 12

44% more call options, than puts

Call options by funds: $5.34M | Put options by funds: $3.72M

8% more funds holding

Funds holding: 71 → 77 (+6)

0% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 17

0.94% less ownership

Funds ownership: 10.15% → 9.21% (-0.94%)

Holders
77
Holders Change
+6
Holders Change %
+8.45%
% of All Funds
1.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
17
Reduced
17
Closed
12
Calls
$5.34M
Puts
$3.72M
Net Calls
+$1.62M
Net Calls Change
-$1.45M

Top Buyers

Rank Fund Capital Flow
1
LC
Lindbrook Capital
California
+$2.98M
2
JP Morgan Chase
JP Morgan Chase
New York
+$933K
3
Jane Street
Jane Street
New York
+$707K
4
Group One Trading
Group One Trading
Illinois
+$489K
5
XT
XTX Topco
Cayman Islands
+$444K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$1.64M
2
Two Sigma Investments
Two Sigma Investments
New York
-$1.06M
3
CSS
Cubist Systematic Strategies
Connecticut
-$723K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$619K
5
EMG
ETF Managers Group
New Jersey
-$612K
Name Holding Trade Value Shares
Change 		Change in
Stake
GJIA
51
Glass Jacobson Investment Advisors
Maryland
$112K +$72.7K +9,350 New
PMFA
52
Plante Moran Financial Advisors
Michigan
$95.2K – – –
EWM
53
Endurance Wealth Management
Rhode Island
$81K – – –
BCM
54
Bourgeon Capital Management
Connecticut
$67.7K – – –
HNB
55
Huntington National Bank
Ohio
$60.8K – – –
Rockefeller Capital Management
56
Rockefeller Capital Management
New York
$48K – – –
CAM
57
Close Asset Management
United Kingdom
$39K – – –
ME
58
McIlrath & Eck
Washington
$36.1K – – –
CG
59
Cutler Group
California
$20K – – –
Northwestern Mutual Wealth Management
60
Northwestern Mutual Wealth Management
Wisconsin
$18.9K – – –
TRCT
61
Tower Research Capital (TRC)
New York
$16K +$8.6K +1,106 +553%
IA
62
IFP Advisors
Florida
$14K – – –
CHC
63
City Holding Co
West Virginia
$12.9K – – –
CFGS
64
Concourse Financial Group Securities
Alabama
$12K – – –
SPIA
65
Steward Partners Investment Advisory
New York
$12K – – –
NFSG
66
Newbridge Financial Services Group
Florida
$7.9K – – –
ASN
67
Advisory Services Network
Georgia
$6.01K +$3.89K +500 New
CA
68
Corrado Advisors
New Jersey
$5.41K +$3.5K +450 New
AWM
69
Activest Wealth Management
Florida
$4.27K – – –
TSWM
70
Tyler-Stone Wealth Management
Ohio
$4K – – –
BCMLT
71
Beacon Capital Management LLC (Tennessee)
Tennessee
$2.63K +$1.7K +219 New
TWA
72
TCI Wealth Advisors
Arizona
$2.41K – – –
BNP Paribas Financial Markets
73
BNP Paribas Financial Markets
France
$1.56K +$8 +1 +0.8%
GRP
74
Global Retirement Partners
California
$1.5K – – –
TF
75
TimeScale Financial
Massachusetts
$810 – – –
1 2
3
4

ORMP Hedge Fund Activity: Q4 2022 in Review

77 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2022, worth a combined $43.2M — up 69% from $25.5M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new ORMP positions and 12 closed out — a net gain of 8 holders — while 17 added to existing stakes and 17 trimmed.

The largest buyer was Lindbrook Capital, opening a new position worth an estimated $2.98M. The largest seller was Morgan Stanley, cutting an estimated $1.64M.

  • 77 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2022, up from 71 in Q3 2022.
  • Funds reported $43.2M of Oramed Pharmaceuticals stock for Q4 2022, up 69% quarter-over-quarter.
  • 20 funds opened new Oramed Pharmaceuticals positions in Q4 2022 and 12 closed out, a net change of +8 holders.
  • The largest Oramed Pharmaceuticals buyer in Q4 2022 was Lindbrook Capital, an estimated $2.98M added.
  • The largest Oramed Pharmaceuticals seller in Q4 2022 was Morgan Stanley, an estimated $1.64M sold.

Based on aggregated 13F filings for Q4 2022.